Trial Profile

Enhancing Immunotherapy by Targeting the EGFR Pathway in Inflammatory Breast Cancer: A Phase II Study of Panitumumab (PmAb) and Pembrolizumab (Pembro) in Combination With Neoadjuvant Chemotherapy (NAC) in Patients With Newly Diagnosed Triple Negative Inflammatory Breast Cancer (TN-IBC)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 03 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Paclitaxel (Primary) ; Panitumumab (Primary) ; Pembrolizumab (Primary)
Indications Breast cancer; Inflammatory breast cancer; Triple negative breast cancer
Focus Therapeutic Use

26 Jul 2023 Planned initiation date changed from 30 Jun 2022 to 11 Mar 2022.
26 Jul 2023 Planned End Date changed from 31 Dec 2028 to 26 Jul 2023.
26 Jul 2023 Planned primary completion date changed from 31 Dec 2028 to 26 Jul 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com